Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2017) 49 EP628 | DOI: 10.1530/endoabs.49.EP628

ECE2017 Eposter Presentations: Diabetes, Obesity and Metabolism Diabetes therapy (52 abstracts)

Effects of dapagliflozin in treatment of gastroparesis considering the state of carbohydrate metabolism in patients with type 2 diabetes mellitus

Iryna Kostitska


Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine.


Diabetic gastroparesis (DG) is associated with high morbidity and is the most common precipitating factor to decompensation of carbohydrate metabolism. SGLT2 inhibitors are becoming a common and useful drug to treat type 2 diabetes. Principle treatment of gastroparesis considering the state of carbohydrate metabolism in patients with type 2 diabetes mellitus are very limited. The aim of this study was to compare the effects of dapagliflozin for management patients with DG. 16 patients with type 2 DM were randomly allocated into 2 groups: a first group (n=8 (3M/5F), mean age was 41.4±6.7 years old, DM during 12.2±5.4 years, body mass index (BMI) was 33.7±1.4 kg/m2) with gastroparesis, and a second (control) group (n=8 (4M/4F), mean age - 45.3±3.9 years old, DM - 13.2±6.2 years, BMI - 32.9±2.5 kg/m2) to take dapagliflozin (daily doses -10 mg) for 3 months. Gastric emptying rate (GER) measurement with the help 13C-octanoic breath test (13C-OBT), prandial and postprandial glucose levels and glycated haemoglobin (HbA1C) were performed at entry and at end of treatment period as well. Low gastric motility has been diagnosed in all patients first group with help of 13C-OBT: T ½ - 98.84±4.22 min, in the second group that result is T ½ - 69.82±9.23 min. After the end of 3 months therapy in the first group significantly improved T ½ -83.11±2.31 min (P<0.05). In the result after treatment we show that glycemic control to be significantly higher (prandial glycemic-7.81±0.6 mmol/l, postprandial – 8.57±0.88 mmol/l, P < 0.05) in the patients of the first group than subjects of the second group (prandial glycemic- 8.44±0.34 mmol/l, postprandial – 9.28±0.13 mmol/l, P>0.05). After treatment level of HbA1C significantly decrease in both groups (P<0.05).Dapagliflozin is an useful drug for treating type 2 diabetes with and without of gastroparesis. Patients with DG get normalization of gastric emptying rate. It appears that this effect may be due to non-specific mechanisms.

Volume 49

19th European Congress of Endocrinology

Lisbon, Portugal
20 May 2017 - 23 May 2017

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.